Caxton Associates (New York)’s AbbVie ABBV Stock Holding History

Caxton Associates (New York)’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$1.34M	Sell	7,566 -6,788	-47%	-$1.25M	0.04%	169
2024 Q3	$2.83M	Buy	14,354 +4,141	+41%	+$773K	0.11%	73
2024 Q2	$1.75M	Sell	10,213 -13,425	-57%	-$2.22M	0.06%	165
2024 Q1	$4.3M	Sell	23,638 -4,360	-16%	-$751K	0.24%	47
2023 Q4	$4.34M	Buy	27,998 +10,466	+60%	+$1.53M	0.22%	64
2023 Q3	$2.61M	Buy	17,532 +276	+2%	+$40.5K	0.36%	50
2023 Q2	$2.32M	Buy	+17,256	New	+$2.53M	0.34%	49
2022 Q4	–	Sell	-2,802	Closed	-$376K	–	435
2022 Q3	$376K	Buy	+2,802	New	+$402K	0.05%	287
2020 Q3	–	Sell	-5,500	Closed	-$540K	–	291
2020 Q2	$540K	Buy	+5,500	New	+$484K	0.05%	122
2020 Q1	–	Sell	-6,539	Closed	-$571K	–	394
2019 Q4	$571K	Buy	+6,539	New	+$543K	0.08%	151
2019 Q3	–	Sell	-16,010	Closed	-$1.16M	–	376
2019 Q2	$1.16M	Buy	+16,010	New	+$1.26M	0.14%	73
2018 Q4	–	Sell	-2,887	Closed	-$273K	–	269
2018 Q3	$273K	Sell	2,887 -5,970	-67%	-$566K	0.02%	334
2018 Q2	$821K	Sell	8,857 -332	-4%	-$32.4K	0.04%	192
2018 Q1	$870K	Buy	+9,189	New	+$1.01M	0.04%	206
2017 Q2	–	Sell	-7,100	Closed	-$463K	–	461
2017 Q1	$463K	Buy	+7,100	New	+$446K	﹤0.01%	269

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Caxton Associates (New York)'s ABBV Position: Q4 2024 in Review

Caxton Associates (New York) reduced its AbbVie (ABBV) stake by 47% in Q4 2024, selling an estimated $1.25M and leaving 7,566 shares worth $1.34M. The position accounts for 0.04% of the portfolio, ranked #169.

Caxton Associates (New York) first reported a position in ABBV in Q1 2017 and has held it in 15 quarters since. The position peaked at $4.34M in Q4 2023. 3,744 funds tracked by Wall St. Rank hold ABBV as of Q4 2024.

Caxton Associates (New York) held 7,566 shares of AbbVie worth $1.34M as of Q4 2024.
Caxton Associates (New York) sold 6,788 AbbVie shares in Q4 2024, an estimated $1.25M.
AbbVie made up 0.04% of Caxton Associates (New York)'s portfolio in Q4 2024, its #169 holding.
Caxton Associates (New York) first reported a position in AbbVie in Q1 2017 and has held it in 15 quarters since.
Caxton Associates (New York)'s AbbVie position peaked at $4.34M in Q4 2023.
3,744 funds tracked by Wall St. Rank held AbbVie as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.